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Commercial dosage formsAbstract A kinetic spectrophotometric method has been developed for the determination of per-
indopril erbumine in pure and commercial dosage forms. The method is based on the reaction of
drug with potassium permanganate in alkaline medium at room temperature (30 ± 1 C). The reac-
tion was followed spectrophotometrically by measuring the increase in absorbance with time at
603 nm and the initial rate, ﬁxed time (at 8.0 min) and equilibrium time (at 90.0 min) methods were
adopted for constructing the calibration graphs. All the calibration graphs are linear in the concen-
tration range of 5.0–50.0 lg/ml. The limits of detection for initial rate, ﬁxed time and equilibrium
time methods were 0.752, 0.882 and 1.091 lg/ml, respectively. The activation parameters such as Ea,
DH, DS and DG were also determined for the reaction and found to be 60.93 kJ/mol, 56.45 kJ/
mol, 74.16 J/K mol and 6.53 kJ/mol, respectively. The variables were optimized and the proposed
methods are validated as per ICH guidelines. The method has been further applied to the determi-
nation of perindopril erbumine in commercial dosage forms. The analytical results of the proposed
methods when compared with those of the reference method show no signiﬁcant difference in accu-
racy and precision and have acceptable bias.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Perindopril erbumine is chemically known as (2S, 3aS, 7aS)-1-
[(S)-N-[(S)-1-carboxybutyl] alanyl] hexahydro-2-indolinecarb-
oxylic acid, 1-ethylester, compound with tert-butylamine
(1:1). It is a pro drug and metabolized in vivo by hydrolysis
of the ester group to form perindoprilat, the biologically active
metabolite. It is an angiotensin converting enzyme inhibitor
(ACE) (Laubie et al., 1984) used to reduce the cardiovascular
S832 N. Rahman et al.risk of individuals with hypertension or post myocardial
infarction and stable coronary disease. The effectiveness of
perindopril as an antihypertensive drug has been demonstrated
in various clinical trials (Lees and Reid, 1987; Herpin et al.,
1989). ACE inhibitors reduce blood pressure by inhibiting
the enzyme which catalyses the conversion of angiotensin I
into angiotensin II. Decreased plasma angiotensin II leads
to an increase in plasma rennin activity and a decrease in
aldosterone. Studies in animals and humans suggest that spe-
ciﬁc and competitive suppression of the rennin–angiotensin–
aldosterone system is the main mechanism by which blood
pressure is reduced. This drug is ofﬁcially listed in the mono-
graph of British Pharmacopoeia (London, 2004), which de-
scribes a potentiometric titration procedure for its assay in
formulations. In order to assure the quantity of perindopril
in pharmaceutical preparations, few analytical methods have
been reported in the literature for the determination of perin-
dopril such as gas chromatography (Lin et al., 1996), high per-
formance liquid chromatography (HPLC) and reversed phased
- HPLC (Medenica et al., 2007; Rani and Sekaran, 2009;
Chaudhary et al., 2010; Pathak et al., 2011; Raju and Rao,
2011), capillary electrophoresis (Hillaert and Bossche, 2000),
atomic absorption spectrophotometry (Abdellatef et al.,
1999) and LC–MS/MS (Jain et al., 2006; Nirogi et al., 2006).
Methods have also been reported based on spectrophotom-
etry for its quantiﬁcation in commercial dosage forms (Abdel-
latef et al., 1998; Abdellatef, 1998; Erk, 2001; Rahman et al.,
2006; Rani et al., 2009; Rahman and Rahman, 2011; Sharma
and Sharma, 2011; Sridevi et al., 2012; Rahman et al., 2012;
Suresh and Sagar, 2012). Kinetic-based spectrophotometric
methods are not widely applied, although they offer the advan-
tage of eliminating additive interferences, which probably af-
fects other methods such as titrimetry and direct
spectrophotometric methods. These methods used in drug
analysis have gained special interest as they offer many advan-
tages over regular analytical techniques. These advantages in-
clude improved selectivity and a decrease of interferences
caused by coloured or turbid samples during testing.
The proposed method describes a validated kinetic spectro-
photometric method for the determination of perindopril erbu-
mine in pure and commercial dosage forms. The method is
based on the reaction of drug with potassium permanganate
in alkaline medium at room temperature (30 ± 1 C) and sub-
sequently the rate of appearance of the green coloured product
was measured at 603 nm. The initial rate, ﬁxed time and equi-
librium time methods are followed for the determination of
perindopril erbumine in commercial dosage forms.
2. Experimental
2.1. Apparatus
All spectrophotometric measurements were made on spectron-
ic 20 D+ spectrophotometer (Milton Roy, USA). A water bath
shaker (NSW 133, New Delhi, India) was used to control the
heating temperature.
2.2. Materials and reagents
Perindopril erbumine was kindly supplied as a gift sample by
Glenmark Pharmaceuticals Ltd. Mumbai, India and used with-
out further puriﬁcation. Commercial tablets of perindoprilerbumine such asCoversyl- 2.0 (SERDIAPharmaceuticals In-
dia Ltd.) and Perigard- 2.0 (Glenmark Pharmaceuticals (Zol-
tan) Ltd., India) were purchased from local pharmacy shop.
(1) 4 · 101 M sodium hydroxide (GR Grade, Merck Lim-
ited, Mumbai, India) solution was prepared in doubly
distilled water.
(2) 9 · 103 M potassium permanganate (GR Grade,
Merck Limited, Mumbai, India) solution was also pre-
pared in doubly distilled water.
2.3. Standard test solution
A 2.264 · 103 M solution of drug by weighing 0.1 g in 100 ml
was prepared in doubly distilled water. The solution was stable
for at least ﬁve days keeping at room temperature (30 ± 1 C)
when protected from direct sun light.
2.4. Recommended procedures for the determination of
perindopril erbumine
2.4.1. Initial rate method
Aliquots of 0.05–0.5 ml of 2.264 · 103 M containing 50–
500 lg of perindopril erbumine were pipetted into a series of
10 ml standard ﬂasks. To each ﬂask, 2.5 ml of 0.40 M NaOH
and 9 · 103 M potassium permanganate were added succes-
sively and then diluted with distilled water at room tempera-
ture (30 ± 1 C). The contents of each ﬂask were mixed well
and measured the increase in absorbance as a function of time
at 603 nm. The initial rate of the reaction (m) at different con-
centrations was evaluated by measuring the slope of the tan-
gent to the absorbance-time plot. The calibration graphs
were obtained by plotting the initial rate of reaction (m) versus
the molar concentration of the perindopril erbumine (C). The
amount of the drug was calculated either from the calibration
curve or regression equation.
2.4.2. Fixed time method
Aﬁxed time of 8.0 minwas selected for thismethod.At this pres-
elected ﬁxed time, the absorbance of each sample of drug solu-
tion was measured at 603 nm against a reagent blank prepared
similarly except drug. The calibration curve was obtained by
plotting the absorbance against the initial concentration of per-
indopril erbumine. The amount of the drugwas computed either
from calibration curve or regression equation.
2.4.3. Equilibrium time method
The equilibrium reaction condition was achieved at 90.0 min
and at this time, the absorbance of each sample of drug solu-
tion was measured at 603 nm against a reagent blank prepared
similarly except drug. The calibration graph was constructed
by plotting the absorbance against the initial concentration
of perindopril erbumine and the concentration of the drug
was calculated either from calibration graph or corresponding
regression equation.
2.5. Procedure for determination of perindopril erbumine in
commercial dosage forms
To determine the content of perindopril in commercial dosage
forms, the contents of 25 tablets were weighed and ﬁnely pow-
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Figure 1 Plot of stoichiometric ratio between perindopril and
KMnO4 (a) logA vs log [Perindopril erbumine] and (b) logA vs log
[KMnO4].
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Kinetic spectrophotometric method for the determination of perindopril erbumine in pure and commercial dosage forms S833dered. A portion of the powder equivalent to 50 mg of active
ingredient was weighed accurately, stirred well with 20 ml dou-
bly distilled water and allowed to stand for 10 min. The residue
was ﬁltered on Whatmann No. 42 ﬁlter paper (Whatman Inter-
national Limited, Kent, UK) and washed with distilled water.
The residue was washed well with doubly distilled water for
complete recovery of drug and was further diluted to give a ﬁ-
nal concentration of 1 mg/ml. An aliquot of the diluted solu-
tion was analysed for perindopril content following the
recommended procedure.
2.6. Limits of detection and quantitation
According to the International Conference on Harmonisation
(ICH) guidelines (Ermer, 2001), the following expressions are
used to evaluate LOD and LOQ.
LOD ¼ 3:3 S0=b and LOD ¼ 10 S0b
where S0 and b are standard deviation and slope of the calibra-
tion line, respectively.
3. Results and discussion
The absorption spectrum of potassium permanganate solu-
tion in the alkaline medium exhibits an absorption band
peaking at 530 nm. The course of the reaction starts on the
addition of alkaline potassium permanganate solution to
the solution of pure perindopril erbumine resulting in the
shift of absorption band peaking at 603 nm. This is all due
to the formation of manganate ion, in the presence of drug.
The intensity of the coloured product increases with time and
therefore a kinetic approach can be exploited for the spectro-
photometric determination of perindopril erbumine in drug
formulations.
The limiting logarithmic method (Rose, 1964) was followed
by performing two sets of the experiments to establish the stoi-
chiometric ratio between perindopril erbumine and potassium
permanganate. In the ﬁrst set of experiment, the concentration
of perindopril erbumine was varied keeping a constant concen-
tration of KMnO4 while in the second set, the concentration of
KMnO4 varied, keeping the constant concentration of perin-
dopril erbumine. LogA versus log [Perindopril erbumine] or
[KMnO4] (Fig. 1a and b) was plotted to calculate the slope
of the respective line to determine the order of reaction of
the drug with respect to KMnO4 or vice versa. The slope
was found to be unity in the ﬁrst case and it was two in mag-
nitude in the second case thus conﬁrming the molar combining
ratio of 1:2 between perindopril erbumine and potassium per-
manganate. Hence, the results indicated that the two moles of
potassium permanganate were consumed by one mole of per-
indopril erbumine. In this reaction, perindopril undergoes
hydrolysis in the presence of NaOH producing ethyl alcohol.
The resulting ethyl alcohol is oxidized by KMnO4/OH
 where-
by the permanganate is reduced to the manganate ion, which is
a coloured species. Therefore, based on the literature back-
ground and our experimental ﬁndings, a reaction mechanism
was proposed and shown in Scheme 1. The proposed mecha-
nism was further proved by treating ethyl alcohol with potas-
sium permanganate in alkaline medium under the same
conditions whereby the coloured product with same absorp-
tion spectrum, was produced.3.1. Optimization of variables
The effect of temperature on the initial rate of reaction was
studied at 303, 308, 313 and 318 K. It was observed that per-
indopril erbumine reacts faster with potassium permanganate
with an increase in temperature. At higher temperatures, the
reaction product may decompose and reproducibility was
not better. To avoid this and for the sake of good results,
the optimum temperature of 303 K was selected for the deter-
mination process.
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Figure 2 Absorbance-time plot for reaction of perindopril with
KMnO4 in alkaline medium: 2.25 · 103 M KMnO4 and (a)
1.13 · 105 (b) 2.26 · 105 (c) 4.53 · 105 (d) 6.79 · 105 (e)
9.06 · 105 and (f) 1.13 · 104 M Perindopril erbumine.
Table 2 Initial rate of reaction at different concentrations of
Perindopril erbumine with [KMnO4] = 2.25 · 103 M and
[NaOH] = 0.10 M.
[Perindopril erbumine]
(mol/l)
Initial rate of reaction,
t (mol/l s)
1.13 · 105 7.92 · 105
2.26 · 105 1.53 · 104
4.53 · 105 3.07 · 104
6.79 · 105 4.60 · 104
9.06 · 105 6.13 · 104
1.13 · 104 7.63 · 104
S834 N. Rahman et al.The effect of the KMnO4 concentration on the initial rate
of reaction (m) was studied in the range of 1.80 · 104–
2.43 · 103 M. The initial rate of reaction was increased with
increase in the concentration of KMnO4 and became constant
at 1.80 · 103 M and remained as such up to 2.43 · 103 M.
Therefore, a concentration of 2.25 · 103 M was used as an
optimum value for the assay procedure. The results are sum-
marized in Table 1.
The effect of concentration of NaOH on the initial rate of
reaction was also studied. The m value increased with increase
in the concentration of NaOH up to 9.2 · 102 M, after which
further increase in the concentration of NaOH resulted in no
change in the initial rate of reaction. Thus, the concentration
of 1.00 · 101 M was found to be optimum in a volume of
10.0 ml.
4. Analytical parameters and method validation
All kinetic parameters were performed under pseudo-ﬁrst or-
der conditions at 30 ± 1 C. The initial rates of the reaction
were determined from absorbance-time plot (Fig. 2) by mea-
suring the slopes of the initial tangent to the absorbance-time
curves and are summarized in Table 2. The kinetic equation
for the reaction of perindopril erbumine in the presence of
potassium permanganate in alkaline medium is written as:
m ¼ dx
dt
¼ kWCnPRPCmKMnO4ClNaOH ðIÞ
For CKMnO4 P 1:80 103M and CNaOH P 9.2 · 102 M
The equationðIÞreduced to dx
dt
¼ kWCn ðIIÞ
The order with respect to perindopril erbumine was deter-
mined from the plot of logarithm of initial rate of reaction
(logm) versus logarithm of molar concentration of perindopril
erbumine (logC) and was found to be unity. Thus, the hydro-
lysis of perindopril erbumine would obey the pseudo ﬁrst order
reaction and equation (II) reduced to
m ¼ dx
dt
¼ kWC ðIIIÞ
where KW is the pseudo ﬁrst order rate constant. Under the
optimized experimental condition, the calibration graph (ini-
tial rate versus C) was found to be linear over the concentra-Table 1 Effect of [KMnO4] and [NaOH] on the initial rate of
reaction at [Perindopril Erbumine] = 1.13 · 104 M.
[KMnO4]
(mol/l)
[NaOH]
(mol/l)
Initial rate of reaction, t (mol/l s)
KMnO4 NaOH
1.80 · 104 0.80 · 102 8.33 · 105 3.38 · 104
5.40 · 104 2.40 · 102 2.50 · 104 4.00 · 104
9.00 · 104 4.00 · 102 3.85 · 104 5.00 · 104
1.26 · 103 5.60 · 102 5.00 · 104 6.00 · 104
1.44 · 103 6.40 · 102 6.53 · 104 6.25 · 104
1.80 · 103 8.00 · 102 7.63 · 104 7.00 · 104
1.89 · 103 9.20 · 102 7.63 · 104 7.63 · 104
1.98 · 103 9.60 · 102 7.63 · 104 7.63 · 104
2.07 · 103 1.00 · 101 7.63 · 104 7.63 · 104
2.25 · 103 1.08 · 101 7.63 · 104 7.63 · 104
2.43 · 103 1.20 · 101 7.63 · 104 7.63 · 104tion range of 5.0–50.0 lg/ml. The regression of initial rate
versus C gave a linear regression equation, m= 2.79 · 104 +
8.99 · 104 C with coefﬁcient of correlation, r= 0.9999. The
conﬁdence limits for the slope of the line of regression and
intercept were computed using the relation a± tSa and
b± tSb at 95% conﬁdence level and found to be 2.79 · 10
4 ± 5.18 · 104 and 8.99 · 104 ± 1.70 · 105, respectively
indicating the high reproducibility of the initial rate method.
The LOD and LOQ were found to be 0.752 and 2.27 lg/ml,
respectively. The variance (S20) was calculated using the equa-
tion (Hartmann et al., 1995):
S20 ¼
Pðmexp t:  mreg:Þ2
n 2
and found to be 4.20 · 108 lg/ml. The low value of variance
suggested the negligible scattering of the experimental data
points around the line of regression.
To evaluate the apparent activation parameters, the reac-
tion rate was studied at 303, 308, 313 and 318 K at [perindopril
erbumine] = 2.26 · 105 M, [KMnO4] = 2.25 · 103 M and
1/T
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Figure 3 Arrhenius plot of lnk vs 1/T at 303, 308, 313 and
318 K: Perindopril erbumine (1.13 · 105–1.13 · 104 M) with
initial concentration of KMnO4 (2.25 · 103 M) and NaOH
(0.1 M) for activation energy (Ea).
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Figure 4 Eyring plot of ln (k/T) versus 1/T at 303, 308, 313 and
318 K: Perindopril erbumine (1.13 · 105–1.13 · 104 M) with
initial concentration of KMnO4 (2.25 · 103 M) and NaOH
(0.1 M) for DH and DS.
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Kinetic spectrophotometric method for the determination of perindopril erbumine in pure and commercial dosage forms S835[NaOH] = 1.00 · 101 M. The Arrhenius plot of lnkobs. versus
1
T
was found to be linear (lnk= lnA - Ea
R
 1
T
) with correlation
coefﬁcient (r2) of 0.9998 ((Fig. 3). Activation energy (Ea) can
be calculated from the slope Ea
R
 
of the Arrhenius plot and
found to be 60.93 kJ/mol. The Eyring plot of lnkobs./T versus
1
T
was linear ðln kobs=T ¼ ln ðkb=hÞ þ DSz=Rþ ðDHz=RÞ  1T
 
S836 N. Rahman et al.with correlation coefﬁcient (r2) of 0.9993 (Fig. 4). The values of
DH and DS were evaluated from the slope (DH/R) and
intercept [ln (kb/h) + DS
/R] of Eyring plot and found to be
56.45 kJ/mol and 74.16 J/K mol, respectively. The value of
Gibbs free energy (DG) of activation of the reaction product
was found to be 6.53 kJ/mol.
In the ﬁxed time method, the absorbance of the coloured
product formed due to the reduction of KMnO4 was recorded
at a preselected ﬁxed time for different concentrations of per-
indopril erbumine. The results indicated a linear increase in
absorbance with time and hence, determination can be done
in a narrow range of time. The calibration graphs were con-
structed by plotting the absorbance against the initial concen-
trations of perindopril erbumine at a ﬁxed time of 2, 4, 6, 8 and
10 min. The important parameters of these calibration curves
are reported in Table 3. It is clear from Table 3 that the most
acceptable values of linearity, intercept, limit of detection and
quantitation were obtained at a ﬁxed time of 8 min. Therefore,
the ﬁxed time of 8 min was selected as the optimum time for
the determination of perindopril erbumine in commercial dos-
age forms.
In the equilibrium time method, the absorbance of green
coloured solution was measured after attaining the equilibrium
(at 90 min) for different concentrations of perindopril erbu-
mine. However, this method requires longer time of analysis
in comparison to the ﬁxed time method. The linear regression
equation and other statistical parameters of this method were
summarized in Table 3.
4.1. Selectivity
Selectivity of the method was ascertained by analysing stan-
dard perindopril in the presence of common excipients suchTable 4 Intra day and inter day assays: test of precision of the init
Proposed methods Amount (lg/ml)
Taken Found ± SDa
Initial rate method
Intra day assay 10.0 10.008 ± 0.066
30.0 29.997 ± 0.059
50.0 50.006 ± 0.051
Inter day assay 10.0 10.001 ± 0.094
30.0 29.998 ± 0.065
50.0 49.997 ± 0.057
Fixed time method
Intra day assay 10.0 9.999 ± 0.065
30.0 30.004 ± 0.123
50.0 49.975 ± 0.123
Inter day assay 10.0 10.004 ± 0.197
30.0 29.975 ± 0.167
50.0 50.004 ± 0.147
Equilibrium time method
Intra day assay 10.0 9.999 ± 0.103
30.0 30.013 ± 0.085
50.0 49.987 ± 0.055
Inter day assay 10.0 9.999 ± 0.065
30.0 29.995 ± 0.140
50.0 50.013 ± 0.085
a Mean for ﬁve independent analyses.
b SAE, standard analytical error.
c C.L., conﬁdence limit at 95% conﬁdence level and four degrees of freas lactose, magnesium stearate, cellulose and silicon dioxide.
The methods show no interference from the excipients.
4.2. Accuracy and precision
The accuracy and precision of the proposed methods were
established by measuring the content of perindopril erbumine
at three different concentration levels on each day as well as
on ﬁve consecutive days. The intra day assay (or the daily pre-
cision) was performed by measuring ﬁve independent analyses
at 10.0, 30.0 and 50.0 lg/ml concentration levels within one
day and inter day assay (or within day precision) was done
at the same speciﬁed levels of concentration by measuring ﬁve
replicate analyses on ﬁve consecutive days (Table 4). The re-
sults of standard deviation, relative standard deviation and
mean recoveries obtained by intra day and inter day precisions
for initial rate, ﬁxed time and equilibrium ﬁxed time methods
are acceptable and can be considered to be very satisfactory.
Performing recovery experiments through standard addition
method also checked the validity of the proposed methods. For
this, a known amount of the pure drugwas added to preanalysed
dosage forms at two concentration levels by measuring ﬁve rep-
licate analyses following the recommended procedures for the
determination of active drug. The results are summarized in Ta-
ble 5, which showed excellent recoveries (99.95%–100.10%)
with low values of relative standard deviations (0.15%–
0.84%). It is also clear from the data that no interference from
the common excipients used in tablets was observed.
4.3. Evaluation of bias
The point and interval hypothesis tests have been performed to
compare results of the proposed methods (with those of theial rate, ﬁxed time and equilibrium time methods.
Recovery (%) RSDa (%) SAEb C.L.c
100.08 0.660 0.030 0.082
99.99 0.197 0.027 0.074
100.01 0.102 0.023 0.064
100.01 0.937 0.042 0.116
99.99 0.216 0.029 0.081
99.99 0.114 0.026 0.071
99.99 0.645 0.029 0.080
100.02 0.410 0.055 0.153
99.95 0.246 0.055 0.153
100.04 1.969 0.088 0.245
99.92 0.559 0.075 0.208
100.01 0.294 0.066 0.182
99.99 1.033 0.046 0.128
100.04 0.284 0.038 0.106
99.97 0.109 0.025 0.068
99.99 0.654 0.029 0.081
99.99 0.465 0.062 0.173
100.03 0.170 0.038 0.106
edom (t= 2.776).
Table 5 Standard addition method for the determination of perindopril erbumine in commercial dosage forms.
Formulations Initial rate method Recovery
(%)
SAE C.L. Fixed time method Recovery (%) SAE C.L
Amount
(lg/ ml)
Amount
(lg/ ml)
Taken Added Found ± SDa Taken Added Found ± SDa
Coversyl 2.0 (SERDIA) 10.0 10.0 19.999 ± 0.062 99.99 0.028 0.077 10.0 10.0 19.990 ± 0.167 99.95 0.075 0.208
10.0 25.0 34.996 ± 0.051 99.99 0.023 0.063 10.0 25.0 34.997 ± 0.123 99.99 0.055 0.153
Perigard 2.0
(Glenmark, Zoltan)
10.0 10.0 20.008 ± 0.079 100.04 0.035 0.098 10.0 10.0 20.019 ± 0.123 100.10 0.055 0.153
10.0 25.0 34.996 ± 0.060 99.99 0.027 0.075 10.0 25.0 35.026 ± 0.232 100.08 0.104 0.288
a Mean for ﬁve independent analyses.
Table 6 Point and interval hypothesis tests: comparison of the proposed methods with the reference method at 95% conﬁdence level.
Formulations Initial rate method Fixed time method Equilibrium time method Reference method
Recovery (%) RSD (%) Recovery (%) RSD (%) Recovery (%) RSD (%) Recovery (%) RSD (%)
Coversyl 2.0
(SERDIA)
99. 99 0.31 100.10 0.61 99.99 0.45 99.94 0.38
hL = 0.994 hU = 1.006 hL = 0.989 hU = 1.007 hL = 0.992 hU = 1.006
t= 0.228 F= 1.503 t= 0.497 F= 2.576 t= 0.185 F= 1.402
Perigard 2.0 100.04 0.39 99. 95 0.84 99.90 0.52 99. 99 0.37
(Glenmark, Zoltan) hL = 0.993 hU = 1.007 hL = 0.989 hU = 1.011 hL = 0.992 hU = 1.009
t= 0.208 F= 1.111 t= 0.100 F= 5.071 t= 0.310 F= 1.97
Theoretical t- (m= 8) and F-values (m= 4, 4) at 95% conﬁdence level are 2.306 and 6.39, respectively hL and hU are within the acceptable limits
of ±2%.
Kinetic spectrophotometric method for the determination of perindopril erbumine in pure and commercial dosage forms S837reference method at 95% conﬁdence level (Table 6). The test
method is considered acceptable when its true mean is
within ± 2.0% of that of the reference methods. This can be
written as
0:98 < l2=l1 < 1:02
which can be generalized to
hL < l2=l1 < hu
where hL and hU are lower and upper acceptance limits, respec-
tively which were calculated from the following quadratic
equation (Acceptable methods, 1992).
h2ðx21  S2pt2=n1Þ  2hx1x2 þ h2ðx22  S2pt2=n2Þ ¼ 05. Applicability of the proposed methods
The initial rate, ﬁxed time and equilibrium time methods were
successfully applied to the determination of perindopril erbu-
mine in commercial dosage forms. The results of the proposed
methods were compared with those of the reference method
(Abdellatef, 1998) using point and interval hypothesis tests
and are summarized in Table 6. The calculated t- (paired)
and F- values at 95% conﬁdence level do not exceed the theo-
retical ones indicating no signiﬁcant differences between the
performance of the proposed methods and the reference meth-
od. A bias of ± 2%, which is based on recovery experiments,
is permissible by The Canadian Health Protection Branch
(Acceptable methods, 1992). Therefore, the acceptable limit
lies within /L = 0.98 and /U = 1.02. It is evident from Table6 that the true bias of all samples of drug is smaller than ± 2%
and thus conﬁrming that the proposed methods are reliable
with acceptable recovery.
6. Conclusions
The proposed kinetic method is sensitive with a simple calibra-
tion system that does not require any laborious clean up pro-
cedure prior to analysis and performed at room temperature
(30 ± 1 C). Moreover the present technique has the advan-
tage of using inexpensive and easily available low cost reagents
and therefore can be frequently used in the laboratories of re-
search, hospitals and pharmaceutical industries. The proposed
methods can be used as alternative methods to reported ones
for routine determination of perindopril erbumine in the pure
form and in commercial dosage forms.Acknowledgement
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